GH Research (GHRS) Competitors $11.94 -0.54 (-4.33%) Closing price 04:00 PM EasternExtended Trading$11.96 +0.02 (+0.13%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GHRS vs. MOR, HCM, BHC, OGN, KNSA, GMTX, CGON, ALVO, CPRX, and TARSShould you be buying GH Research stock or one of its competitors? The main competitors of GH Research include MorphoSys (MOR), HUTCHMED (HCM), Bausch Health Cos (BHC), Organon & Co. (OGN), Kiniksa Pharmaceuticals International (KNSA), Gemini Therapeutics (GMTX), CG Oncology (CGON), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry. GH Research vs. Its Competitors MorphoSys HUTCHMED Bausch Health Cos Organon & Co. Kiniksa Pharmaceuticals International Gemini Therapeutics CG Oncology Alvotech Catalyst Pharmaceuticals Tarsus Pharmaceuticals GH Research (NASDAQ:GHRS) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment. Do analysts rate GHRS or MOR? GH Research currently has a consensus price target of $32.00, indicating a potential upside of 168.01%. Given GH Research's stronger consensus rating and higher possible upside, analysts clearly believe GH Research is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, GHRS or MOR? GH Research has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Is GHRS or MOR more profitable? GH Research has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. GH Research's return on equity of -16.71% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -16.71% -16.06% MorphoSys -226.79%-694.31%-22.55% Which has stronger valuation & earnings, GHRS or MOR? GH Research has higher earnings, but lower revenue than MorphoSys. GH Research is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.74-16.14MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Does the media refer more to GHRS or MOR? In the previous week, GH Research had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for GH Research and 0 mentions for MorphoSys. GH Research's average media sentiment score of 1.58 beat MorphoSys' score of 0.00 indicating that GH Research is being referred to more favorably in the media. Company Overall Sentiment GH Research Very Positive MorphoSys Neutral Do insiders and institutionals believe in GHRS or MOR? 56.9% of GH Research shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryGH Research beats MorphoSys on 12 of the 15 factors compared between the two stocks. Get GH Research News Delivered to You Automatically Sign up to receive the latest news and ratings for GHRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GHRS vs. The Competition Export to ExcelMetricGH ResearchMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$649.31M$3.20B$5.86B$10.15BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-16.1321.1774.5225.93Price / SalesN/A473.02539.62123.65Price / CashN/A46.6837.5660.44Price / Book3.479.6112.166.29Net Income-$38.96M-$53.29M$3.28B$270.77M7 Day Performance-15.26%0.29%0.98%3.36%1 Month Performance-1.65%8.91%7.20%6.41%1 Year Performance41.13%13.14%63.06%28.26% GH Research Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GHRSGH Research2.5362 of 5 stars$11.94-4.3%$32.00+168.0%+53.3%$649.31MN/A-16.1310MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730HCMHUTCHMED2.6066 of 5 stars$16.11+0.9%$28.00+73.8%-2.6%$2.79B$630.20M0.001,811News CoverageAnalyst DowngradeGap UpBHCBausch Health Cos4.6295 of 5 stars$7.33-0.3%$9.00+22.9%+13.7%$2.72B$9.63B28.1720,700Positive NewsOGNOrganon & Co.4.5156 of 5 stars$10.48+0.9%$17.33+65.5%-47.1%$2.70B$6.40B3.894,000Positive NewsKNSAKiniksa Pharmaceuticals International2.1473 of 5 stars$36.57+2.4%$41.17+12.6%+52.1%$2.65B$423.24M914.48220Short Interest ↑GMTXGemini TherapeuticsN/A$60.76+0.9%N/A+21.0%$2.63BN/A-60.7630CGONCG Oncology2.185 of 5 stars$33.69+1.9%$53.91+60.0%-9.2%$2.52B$1.14M-19.0361Gap UpHigh Trading VolumeALVOAlvotech3.2488 of 5 stars$8.16-2.0%$14.00+71.6%-25.2%$2.51B$491.98M35.481,032Short Interest ↓CPRXCatalyst Pharmaceuticals4.9144 of 5 stars$20.08-1.0%$33.20+65.3%+4.1%$2.48B$491.73M12.1780Positive NewsInsider TradeTARSTarsus Pharmaceuticals2.7356 of 5 stars$56.89-1.3%$66.67+17.2%+63.1%$2.43B$182.95M-24.4250Positive NewsInsider Trade Related Companies and Tools Related Companies MorphoSys Alternatives HUTCHMED Alternatives Bausch Health Cos Alternatives Organon & Co. Alternatives Kiniksa Pharmaceuticals International Alternatives Gemini Therapeutics Alternatives CG Oncology Alternatives Alvotech Alternatives Catalyst Pharmaceuticals Alternatives Tarsus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GHRS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GH Research PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share GH Research With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
